Market Place
Sourcing Support
Neurocrine Biosciences Shows Durable Hormone Control
01 May 2026 //
PR NEWSWIRE
Nxera Pharma Initiates Phase 2 Trial Of NBI-1117570
12 Apr 2026 //
GLOBENEWSWIRE
Neurocrine Biosciences Reports 2025 Results and 2026 Outlook
11 Feb 2026 //
PR NEWSWIRE
Neurocrine Biosciences Starts Phase 2 Trial For NBI-1065890
26 Jan 2026 //
PR NEWSWIRE BIO
Neurocrine Biosciences Shows INGREZZA Outperforms AUSTEDO XR
15 Jan 2026 //
PR NEWSWIRE
Neurocrine Biosciences Highlights R&D Transformation
16 Dec 2025 //
PR NEWSWIRE
Neurocrine Publishes Review Highlighting Unique INGREZZA Profile
20 Nov 2025 //
PR NEWSWIRE
Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail
11 Nov 2025 //
FIERCE BIOTECH
Neurocrine Biosciences Updates Phase 2 Study Of NBI-1070770
11 Nov 2025 //
PR NEWSWIRE
Neurocrine Pens $880M Pact With Transthera For Immunology Target
04 Nov 2025 //
FIERCE BIOTECH
Neurocrine Shows INGREZZA Efficacy in KINECT 4 Analysis
17 Oct 2025 //
PR NEWSWIRE
Neurocrine Bio Appoints Mike Sibley as Senior Vice President
06 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences Shows Ingrezza Sustained Benefits
06 Oct 2025 //
PR NEWSWIRE
Neurocrine Biosciences Shows Ingrezza® Capsules Prompt Early
23 Sep 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Unveil Osavampator Phase 2 Data
17 Sep 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Canaccord Genuity Conference
07 Aug 2025 //
PR NEWSWIRE
Neurocrine Shows 1-Year CRENESSITY® Results at ENDO 2025
14 Jul 2025 //
PR NEWSWIRE
Neurocrine Biosciences Starts Phase 1 Study for NBIP-01435
30 Jun 2025 //
PR NEWSWIRE
Neurocrine: Ingezza Cuts HD Chorea Burden in KINECT-HD Study
27 Jun 2025 //
PR NEWSWIRE
Nxera Pharma gets US$15M from Neurocrine Biosciences for Phase 3
02 Jun 2025 //
GLOBENEWSWIRE
Neurocrine Biosciences Presents Data on Tardive Dyskinesia
16 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present One-Year Data at PES 2025
16 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences Reveals Crenessity Reduces Glucocorticoid
08 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Investor Conferences in May
06 May 2025 //
PR NEWSWIRE
Neurocrine Biosciences Presents 48-Week Remission Data on INGREZZ
20 Mar 2025 //
PR NEWSWIRE
Neurocrine Biosciences Shows INGREZZA Reduces Chorea Across Body
17 Mar 2025 //
PR NEWSWIRE
Neurocrine Biosciences to Present at Stifel 2025 CNS Forum
11 Mar 2025 //
PR NEWSWIRE
Neurocrine Biosciences Starts Phase 1 Study of NBI-1140675
05 Mar 2025 //
PR NEWSWIRE
US FDA approves Neurocrine Biosciences` genetic disorder drug
14 Dec 2024 //
REUTERS
Neurocrine Biosciences at TD Cowen Neuropsychiatry Summit
19 Sep 2024 //
PRESS RELEASE
Neurocrine Biosciences Updates On Luvadaxistat Phase 2 Data
12 Sep 2024 //
PR NEWSWIRE
Nxera Partner Neurocrine Initiates NBI-1117567 Phase 1 Study
09 May 2024 //
GLOBENEWSWIRE
Sentia and Neurocrine Extend Collaboration to Discover Novel CRF Peptides
16 Apr 2024 //
GLOBENEWSWIRE
BlackRock Inc. Ups Stake in Neurocrine Biosciences, Inc. (NBIX)
23 Jan 2023 //
NASDAQ
Voyager nets up to $1.7 billion in Neurocrine gene therapy pact
10 Jan 2023 //
GLOBENEWSWIRE
